Research into rheumatoid arthritis has revealed a new target for treatment of the condition.
Scientists at Harvard medical school have identified peptide molecules, which can restrict immune cell responses thought to be important in diseases such as arthritis.
Working in co-ordination with Swiss pharmaceuticals giant, Roche, the researchers are working on the development of a synthetic version of the peptide to aid in the treatment of the condition.
Whilst the discovery is seen as an important development into the understanding of the disease, reports suggest that the treatment is still a long way from being completed.
Madeleine Devey of the Arthritis Research Campaign told The Guardian that she believed the treatment was "miles away", noting that the scientists had yet to reach the stage of animal tests.
© 1998-2004 DeHavilland Information Services plc. All rights reserved.